AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06416020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HC-MOUD Only
Description: MOUD with buprenorphine provided in a hub buprenorphine clinic
Study NCT06416020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BT-MOUD with Buprenorphine
Description: MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
Study NCT05297929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan Tablet
Description: Drug: Irbesartan Oral administration on an empty stomach／fed condition
Study NCT05581433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Cooling Spray
Description: The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
Study NCT05581433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray as Placebo
Description: Application of saline spray without cooling effect to the area to be injected for placebo purposes
Study NCT04571801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard diagnostics
Description: Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
Study NCT04571801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing (NGS)
Description: Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
Study NCT06214702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: ELISA estimation of PLGF, sFlt-1 and Serpin C
Study NCT05049928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation solution (m-Rehab)
Description: The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects
Study NCT05391581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: Selective antagonist of the GIPR, GIP(3-30)NH2
Study NCT05391581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2R antagonist / study tool
Description: Selective antagonist of the GLP-2R, GLP-2(3-33)
Study NCT05391581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline
Study NCT05391581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT05391581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06272045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRICH
Description: In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.
Study NCT06272045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Home Visiting
Description: Usual home visiting without cardiovascular health promotion content
Study NCT06598371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study NCT06598371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV
Study NCT06598371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-004EX
Description: Given by IV
Study NCT06598371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given by IV
Study NCT04659629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL-201
Description: NL-201 is a de novo protein therapeutic.
Study NCT04659629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: A programmed death receptor-1 (PD-1)-blocking antibody
Study NCT05350514 — intervention group
Intervention type: DRUG
Intervention: PI-2620 tracer
Description: Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
Study NCT04041479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the DMPFC or left DLPFC
Study NCT04041479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the DMPFC or left DLPFC
Study NCT06621498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation technique
Description: Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
Study NCT06621498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge preservation
Description: Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
Study NCT06621498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge preservation
Description: Tooth extraction, full-thickness graft harversting and socket sealing with it.
Study NCT06619119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excape room simulation
Description: Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time.
Study NCT06620250 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Prevention and control of myopia
Description: The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
Study NCT06631846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses.
Study NCT06631846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
Study NCT06631846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy and mindfulness meditation
Description: Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
Study NCT06631846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
Study NCT06730802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
Study NCT06730802 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Statin
Description: the control group will receive standard statin therapy.
Study NCT06731114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle release
Description: Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total
Study NCT06731114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks
Study NCT06731114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid release
Description: Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
Study NCT05262712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
Study NCT05262712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Devices mounted, no stimulation
Study NCT06477835 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM0718 Injection
Description: Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
Study NCT06477835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SIM0718 Injection
Description: Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
Study NCT05215912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-738
Description: TNB-738 is an investigation drug. Other: Matching placebo
Study NCT04940715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive joint mobilization
Description: Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (>50% of maximum therapist strength), according to patient's irritability and severity.
Study NCT04940715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
Study NCT05564650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT05564650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04041479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the left DLPFC
Study NCT05851924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Description: Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle
Study NCT05851924 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AD-XRT and Capecitabine
Description: The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
Study NCT05564650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT05564650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05564650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05564650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT06591767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 200 mg supplemental Quercefit®
Study NCT06591767 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Berberol K®
Description: Berberine Phytosome® 730 mg~+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract
Study NCT05085808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
Study NCT05085808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
Study NCT05085808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
Study NCT06625645 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Modified triple antibiotic paste (TAP) mixed with chlorehexidine
Description: M-TAP with CHX 2%
Study NCT06625645 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Modified Triple Antibiotic Paste mixed with saline
Description: M-TAP mixed with saline
Study NCT06625645 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide mixed with chlorohexidine Intracanal medication
Description: calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
Study NCT06625645 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide mixed with saline as intracanal medication
Description: calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
Study NCT06127966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
Study NCT06127966 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).
Description: The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
Study NCT05564650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06426134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
Description: 1x50g ingestion of pure dGK
Study NCT06426134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride
Description: Isocaloric carbohydrate control (active control)
Study NCT06244030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization group
Description: The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
Study NCT05861102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
Study NCT05861102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally twice daily for 16 weeks
Study NCT06533852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiome Transplantation (FMT)
Description: Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months.
Study NCT06533852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMT Placebo
Description: Two doses:~First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months.
Study NCT06027632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive exercises with supervision
Description: The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed